Prazepam (Assayed as Nordiazepam)
Also known as: PRAZE
Use
This test is used to optimize dosing and monitor patient adherence to Prazepam treatment, which is metabolized to Nordiazepam. It helps to ensure therapeutic levels are maintained while avoiding toxicity, essential for effective therapeutic drug monitoring.
Special Instructions
Timing of specimen collection is critical: Predose (trough) draw at steady state concentration is recommended. Patients should adhere to this timing to ensure accurate measurement of drug levels.
Limitations
Prazepam itself is not detected in serum due to its rapid metabolism to Nordiazepam. The assay only measures Nordiazepam levels. Adverse effects of Prazepam may include dizziness, fatigue, drowsiness, ataxia, and weakness, which need to be considered in the clinical interpretation of the test results.
New York Approved
Methodology
Mass Spectrometry
Biomarkers
LOINC Codes
- 3977-6
Result Turnaround Time
1-7 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL
Minimum Volume
1 mL
Container
ARUP standard transport tube
Collection Instructions
Collect using a gray (potassium oxalate/sodium fluoride) tube. Plain red, green (sodium heparin), lavender (K2 or K3EDTA), or pink (K2EDTA) tubes are also acceptable.
Patient Preparation
Predose (trough) draw at steady state concentration.
Storage Instructions
Refrigerated.
Causes for Rejection
Gel separator tubes and plasma or whole blood collected in light blue (sodium citrate) tubes. Hemolyzed specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 1 week |
| Refrigerated | 2 weeks |
| Frozen | 3 years |
Other tests from different labs that may be relevant